Protara Therapeutics Inc. has received both Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA) for its investigational therapy TARA-002, aimed at treating pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs). Additionally, TARA-002 was selected to participate in the FDA's Chemistry, Manufacturing, and Controls $(CMC)$ Development and Readiness Pilot (CDRP) Program, which supports the development of therapies with expedited clinical timelines. The therapy had previously been granted Rare Pediatric Disease designation for the treatment of LMs. No other beneficiary organizations were mentioned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9619549) on January 05, 2026, and is solely responsible for the information contained therein.